Aimmune Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aimmune Therapeutics, Inc.
Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.
The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.
- Other Names / Subsidiaries
- Allergen Research Corporation (ARC)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.